(Reuters) - Amgen Inc halted a late-stage trial of an experimental drug for pancreatic cancer after independent reviewers concluded that it was unlikely to significantly help patients.
Amgen said the trial of ganitumab, also known as AMG479, did not raise any safety concerns. The company said it would also stop a separate mid-stage trial of the drug.
"These disappointing results underscore the difficulty of treating pancreatic cancer, which remains an unmet medical need," Sean Harper, head of research and development at Amgen, said in a statement.
(Reporting By Deena Beasley; Editing by Bernard Orr)
pacific standard time northern mariana islands summer time coolio daylight savings time 2012 ricky rubio day light savings time
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.